Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness
Status:
Recruiting
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This multi-site Phase 3 clinical trial is a randomized, double-blind, placebo-controlled and
open label active-controlled study to identify the safety and efficacy of a repeated-dose
regimen of DPI-386 nasal gel (intranasal scopolamine gel) for the prevention and treatment of
motion sickness. The study will be conducted aboard Navy fleet or Marine ships undergoing
military operations to obtain data in an operationally relevant real world environment.